Phase I/II Study of hLL1 in Multiple Myeloma

NCT00421525 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Myeloma, Plasma-Cell
PLASMACYTOMA

Interventions

BIOLOGICAL: milatuzumab

Sponsor

Gilead Sciences